Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase 3

Terminated

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: celecoxib
Drug: gemcitabine hydrochloride
Other: placebo
Drug: pemetrexed disodium

First Posted Date: 2010-01-01

Last Posted Date: 2018-07-23

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 313

Registration Number: NCT01041781

Locations: 🇺🇸
Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States
🇺🇸
Toledo Clinic Cancers Centers - Maumee, Maumee, Ohio, United States
🇺🇸
Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States

and more 395 locations

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer

Phase 2

Terminated

Conditions: Endometrial Adenocarcinoma
Stage II Uterine Corpus Cancer
Stage IVA Uterine Corpus Cancer
Stage IB Uterine Corpus Cancer
Stage IIIA Uterine Corpus Cancer
Stage IIIC Uterine Corpus Cancer
Stage IVB Uterine Corpus Cancer
Stage IA Uterine Corpus Cancer
Stage IIIB Uterine Corpus Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Radiation: Internal Radiation Therapy
Radiation: External Beam Radiation Therapy
Other: Laboratory Biomarker Analysis

First Posted Date: 2009-12-30

Last Posted Date: 2023-10-26

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 31

Registration Number: NCT01041027

Locations: 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States

First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Non Small Cell Lung Cancer

First Posted Date: 2009-12-23

Last Posted Date: 2014-12-04

Lead Sponsor: Vejle Hospital

Target Recruit Count: 23

Registration Number: NCT01038037

Locations: 🇩🇰
Vejle Hospital, Vejle, Denmark

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Panitumumab
Drug: Nab-paclitaxel
Drug: Carboplatin
Drug: 5-Fluorouracil
Drug: Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2009-12-21

Last Posted Date: 2023-03-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 47

Registration Number: NCT01036087

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors

Phase 1

Withdrawn

Conditions: Tumors

First Posted Date: 2009-12-14

Last Posted Date: 2013-05-13

Lead Sponsor: University of California, San Francisco

Registration Number: NCT01031212

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Completed

Conditions: Recurrent Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: cisplatin
Drug: carboplatin
Other: questionnaire administration

First Posted Date: 2009-12-04

Last Posted Date: 2018-07-05

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 45

Registration Number: NCT01026467

Locations: 🇺🇸
Syracuse VA Medical Center, Syracuse, New York, United States
🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Conditions: Lung Cancer

First Posted Date: 2009-12-03

Last Posted Date: 2013-08-12

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 26

Registration Number: NCT01024712

Locations: 🇨🇳
Cancer Institute Hospital, Chinese Academy of Medical Sciences, Beijing, China

Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer

Phase 2

Withdrawn

Conditions: Head and Neck Neoplasms

Interventions: Drug: Cetuximab
Drug: Carboplatin
Drug: Vinorelbine

First Posted Date: 2009-11-26

Last Posted Date: 2020-11-02

Lead Sponsor: Per Pfeiffer

Registration Number: NCT01020864

Locations: 🇩🇰
Department of Oncology, Odense University Hospital, Odense, Denmark

A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients

Phase 4

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2009-11-26

Last Posted Date: 2013-08-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 109

Registration Number: NCT01020786

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yamaguchi, Japan

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

Phase 3

Completed

Conditions: Ovarian Neoplasms
Peritoneal Neoplasms

Interventions: Drug: BIBF 1120
Drug: Placebo
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-11-18

Last Posted Date: 2017-12-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1366

Registration Number: NCT01015118

Locations: 🇺🇸
1199.15.10019 Boehringer Ingelheim Investigational Site, Bismarck, North Dakota, United States
🇺🇸
1199.15.10024 Boehringer Ingelheim Investigational Site, Canton, Ohio, United States
🇺🇸
1199.15.10107 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States

and more 278 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy